Skip to content
Information for healthcare professionals

Search Research

Contact Us

Fujimori et al (2007) High dose probiotic and prebiotic co-therapy for remission induction of active Crohn’s disease

Fujimori et al (2007) High dose probiotic and prebiotic co-therapy for remission induction of active Crohn’s disease

Citation

Fujimori S, Tatsuguchi A, Gudis K, Kishuda T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C (2007) High dose probiotic and prebiotic co-therapy for remission induction of active Crohn’s disease. Journal of Gastroenterology & Hepatology 22: 1199-1204.

Objective

To assess the benefit of a combination of prebiotic and high dose probiotic for treatment of active Crohn’s disease (CD).

Methods

The ten patients recruited had active CD but had not undergone any prior surgery for the condition. Their earlier treatment with aminosalicyclates and prednisolone had not resulted in remission; the main symptoms suffered were diarrhoea and abdominal pain.

The patients were given oral probiotic and prebiotic daily for varying periods ranging from seven to 21 months. The probiotic contained Bifidobacterium breve (30 x 109 CFU), B. longum (15 x 109 CFU) and Lactobacillus casei (LcS, 30 x 109 CFU) and was consumed once daily.  The prebiotic (psyllium at 3.3g) was consumed three times a day. Patients were free to reduce their intake of probiotic or prebiotic during the course of the trial.

Crohn’s disease activity index (CDAI), International Organisation for the Study of Inflammatory Bowel Disease (IOIBD) scores and blood samples were measured pre- and post-intervention. 

Results

Average trial duration was 13.0 ± 4.5 months. By the end of the intervention period, average daily intake of probiotic was 45 ± 24 109 CFU; six patients had also taken 7.9 ± 3.6 g psyllium per day. Seven patients taking the synbiotic combination showed an improvement in their clinical condition. Two patients were able to stop steroid therapy, and four decreased their intake.

A significant reduction was seen in CDAI and IOIBD scores after synbiotic therapy (P = 0.009, P = 0.03 respectively) as well as a significant reduction in incidence of daily diarrhoea (P = 0.009) and abdominal pain index scores (P = 0.046). Analysis of blood samples showed no statistical differences associated with the intervention. No adverse effects were reported.

Conclusions

The high dose synbiotic combination was associated with reduced CD activity and achievement of remission. Larger, randomised controlled trials are needed to confirm these findings.

 
Back to top